22 results
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
IgM and Non-IgM ... of Progression #EBM ... #Honc #MGUS #Progression ... #IgM #NonIgM #MultipleMyeloma ... #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Progression of MGUS ... Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM
Common Causes of the Different Categories of Dizziness #Diagnosis #PrimaryCare #EM #IM #Differential #Dizziness #Vertigo #Disequilibrium
#PrimaryCare #EM ... #IM #Differential ... Lightheadedness #Table #NEJM
DSM5 Diagnostic Criteria for Delirium #Diagnosis #IM #Delirium #DSM5 #NEJM
Delirium #Diagnosis #IM ... Delirium #DSM5 #NEJM
Approaches to Evaluating Kidney Disease in Patients with HIV Infection #Pathophys #Nephro #IM #HIV #CKD #AKI
Pathophys #Nephro #IM ... HIV #CKD #AKI #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
to Trial Group #EBM ... #Neuro #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM
Kinetics of Viral and Serologic Responses after Exposure to West Nile Virus. #Diagnosis #IM #InfectiousDisease #WestNile
#Diagnosis #IM # ... WestNile #Viremia #IgM ... #Detection #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #NEJM
Pathogenesis of Nonalcoholic Steatohepatitis. Various factors, including inflammation, hyperinsulinemia or insulin resistance, and altered lipid homeostasis,
Pathophysiology #GI #IM ... NonAlcoholicFattyLiverDisease #NEJM